outcome of Board Meeting ,where the board has approved and consider the appointment of statutory auditor to fill the casual vacancy and also the resignation of Chief Finance Officer.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Kimia Biosciences Ltd held a meeting on April 23, 2025 with three key outcomes. First, the statutory auditor Sunil Suresh & Associates (FRN: 011646N) resigned on April 22, 2025, citing inability to continue; the audit committee noted no concerns were raised and found the grounds convincing. Second, M/s Neeraj Arora & Associates (FRN: 021309N) has been recommended as the new statutory auditor to fill the casual vacancy until the 32nd AGM, and for a further five-year term until the 37th AGM in 2029, subject to shareholder approval. Third, CFO Mr. Rakesh Chetani resigned for personal reasons and to pursue other career opportunities, with his last working day being May 11, 2025.
Shareholders should note two simultaneous top-level exits (auditor and CFO) within a short window, which may raise short-term governance concerns even though no audit issues were flagged. The quick appointment of a replacement auditor and the personal-reason nature of the CFO exit soften the impact, but investors may want clarity on succession plans for the CFO role.